Boundless Bio, Inc. Common Stock
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by interrogating extrachromosomal DNA (ecDNA). The company's lead product candidate is BBI-355, an ecDNA-directed therapeutic candidate and oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene ampli… Read more
Boundless Bio, Inc. Common Stock (BOLD) - Net Assets
Latest net assets as of September 2025: $110.17 Million USD
Based on the latest financial reports, Boundless Bio, Inc. Common Stock (BOLD) has net assets worth $110.17 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($168.72 Million) and total liabilities ($58.55 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $110.17 Million |
| % of Total Assets | 65.3% |
| Annual Growth Rate | 2.95% |
| 5-Year Change | -65.98% |
| 10-Year Change | N/A |
| Growth Volatility | 118.98 |
Boundless Bio, Inc. Common Stock - Net Assets Trend (2016–2024)
This chart illustrates how Boundless Bio, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Boundless Bio, Inc. Common Stock (2016–2024)
The table below shows the annual net assets of Boundless Bio, Inc. Common Stock from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $150.64 Million | +218.54% |
| 2023-12-31 | $-127.08 Million | -55.55% |
| 2022-12-31 | $-81.70 Million | -113.93% |
| 2021-12-31 | $-38.19 Million | -108.63% |
| 2018-12-31 | $442.75 Million | +182.73% |
| 2017-12-31 | $156.60 Million | +31.19% |
| 2016-12-31 | $119.37 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Boundless Bio, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10106100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | 0.00% |
| Other Comprehensive Income | $121.00K | 0.08% |
| Other Components | $351.99 Million | 233.66% |
| Total Equity | $150.64 Million | 100.00% |
Boundless Bio, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Boundless Bio, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SENFONG
KLSE:5308
|
$18.93 Million |
|
INNOVANA
NSE:INNOVANA
|
$18.94 Million |
|
01 Quantum Inc.
F:DFK0
|
$18.94 Million |
|
NFON AG
XETRA:NFN
|
$18.94 Million |
|
Fairvest Ltd
JSE:FTA
|
$18.93 Million |
|
RBW Inc.
KQ:361570
|
$18.93 Million |
|
Change Financial Ltd
AU:CCA
|
$18.92 Million |
|
Feng Ching Metal
TWO:2061
|
$18.92 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Boundless Bio, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -127,082,000 to 150,642,000, a change of 277,724,000.
- Net loss of 65,363,000 reduced equity.
- Share repurchases of 110,000 reduced equity.
- New share issuances of 93,000,000 increased equity.
- Other comprehensive income increased equity by 81,000.
- Other factors increased equity by 250,116,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-65.36 Million | -43.39% |
| Share Repurchases | $110.00K | -0.07% |
| Share Issuances | $93.00 Million | +61.74% |
| Other Comprehensive Income | $81.00K | +0.05% |
| Other Changes | $250.12 Million | +166.03% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Boundless Bio, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.13x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $11.18 | $1.15 | x |
| 2017-12-31 | $5.89 | $1.15 | x |
| 2018-12-31 | $10.06 | $1.15 | x |
| 2021-12-31 | $-1.72 | $1.15 | x |
| 2022-12-31 | $-3.67 | $1.15 | x |
| 2023-12-31 | $-5.71 | $1.15 | x |
| 2024-12-31 | $8.87 | $1.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Boundless Bio, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -43.39%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.37x
- Recent ROE (-43.39%) is below the historical average (-25.73%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -49.99% | 0.00% | 0.00x | 1.19x | $-71.61 Million |
| 2017 | -57.62% | 0.00% | 0.00x | 1.14x | $-105.90 Million |
| 2018 | -29.10% | 0.00% | 0.00x | 1.07x | $-173.10 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-21.39 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-37.73 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-36.73 Million |
| 2024 | -43.39% | 0.00% | 0.00x | 1.37x | $-80.43 Million |
Industry Comparison
This section compares Boundless Bio, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Boundless Bio, Inc. Common Stock (BOLD) | $110.17 Million | -49.99% | 0.53x | $18.93 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |